肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021 Fleischner学会意见书：接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理

2021-01-12 Fleischner学会 Radiology.2021 Jan 12

免疫检查点抑制剂药物相关性肺炎

2021年1月，Fleischner学会发布接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理的意见书。本文主要总结了在分子靶向药物和癌症免疫治疗的新兴时代药物相关性肺

中文标题：

2021 Fleischner学会意见书：接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理

英文标题：

Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society

发布机构：

Fleischner学会

发布日期：

2021-01-12

简要介绍：

2021年1月，Fleischner学会发布接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理的意见书。本文主要总结了在分子靶向药物和癌症免疫治疗的新兴时代药物相关性肺炎的简化诊断标准，CT检查以及管理建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 Fleischner学会意见书：接受分子靶向药物以及免疫检查点抑.pdf)] GetToolGuiderByIdResponse(projectId=1, id=249a71c002039072, title=2021 Fleischner学会意见书：接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理, enTitle=Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society, guiderFrom=Radiology.2021 Jan 12, authorId=0, author=, summary=2021年1月，Fleischner学会发布接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理的意见书。本文主要总结了在分子靶向药物和癌症免疫治疗的新兴时代药物相关性肺, cover=https://img.medsci.cn/2021121/1611241283233_2020535.jpg, journalId=0, articlesId=null, associationId=902, associationName=Fleischner学会, associationIntro=Fleischner学会是一个国际的多学科胸部放射医学会，致力于通过胸部放射学诊断治疗胸部疾病。, copyright=0, guiderPublishedTime=Tue Jan 12 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年1月，Fleischner学会发布接受分子靶向药物以及免疫检查点抑制剂治疗患者药物相关性肺炎的胸部CT诊断和临床管理的意见书。本文主要总结了在分子靶向药物和癌症免疫治疗的新兴时代药物相关性肺炎的简化诊断标准，CT检查以及管理建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=36163, tagName=免疫检查点抑制剂), TagDto(tagId=109459, tagName=药物相关性肺炎)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=40, categoryName=影像放射, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=36163, guiderKeyword=免疫检查点抑制剂, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2368, appHits=158, showAppHits=0, pcHits=479, showPcHits=2210, likes=0, shares=21, comments=7, approvalStatus=1, publishedTime=Thu Jan 21 23:41:11 CST 2021, publishedTimeString=2021-01-12, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Thu Jan 21 23:02:30 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Tue Jan 02 13:50:18 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 Fleischner学会意见书：接受分子靶向药物以及免疫检查点抑.pdf)])
2021 Fleischner学会意见书：接受分子靶向药物以及免疫检查点抑.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1081557, encodeId=29be108155e9b, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5561488012, createdName=luosujuan1984, createdTime=Sat Dec 18 16:13:28 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051057, encodeId=3735105105e53, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:13:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051056, encodeId=74cb1051056e4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:11:59 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970835, encodeId=91cc9e0835cd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31545513340, createdName=ms1000001134092964, createdTime=Fri Jun 04 11:03:34 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952691, encodeId=16019526917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12d22296338, createdName=121f8ba0m90暂无昵称, createdTime=Wed Mar 31 15:56:16 CST 2021, time=2021-03-31, status=1, ipAttribution=)]
    2021-12-18 luosujuan1984

    棒

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1081557, encodeId=29be108155e9b, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5561488012, createdName=luosujuan1984, createdTime=Sat Dec 18 16:13:28 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051057, encodeId=3735105105e53, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:13:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051056, encodeId=74cb1051056e4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:11:59 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970835, encodeId=91cc9e0835cd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31545513340, createdName=ms1000001134092964, createdTime=Fri Jun 04 11:03:34 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952691, encodeId=16019526917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12d22296338, createdName=121f8ba0m90暂无昵称, createdTime=Wed Mar 31 15:56:16 CST 2021, time=2021-03-31, status=1, ipAttribution=)]
    2021-09-14 ms8000000063630784

    好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1081557, encodeId=29be108155e9b, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5561488012, createdName=luosujuan1984, createdTime=Sat Dec 18 16:13:28 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051057, encodeId=3735105105e53, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:13:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051056, encodeId=74cb1051056e4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:11:59 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970835, encodeId=91cc9e0835cd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31545513340, createdName=ms1000001134092964, createdTime=Fri Jun 04 11:03:34 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952691, encodeId=16019526917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12d22296338, createdName=121f8ba0m90暂无昵称, createdTime=Wed Mar 31 15:56:16 CST 2021, time=2021-03-31, status=1, ipAttribution=)]
    2021-09-14 ms8000000063630784

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1081557, encodeId=29be108155e9b, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5561488012, createdName=luosujuan1984, createdTime=Sat Dec 18 16:13:28 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051057, encodeId=3735105105e53, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:13:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051056, encodeId=74cb1051056e4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:11:59 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970835, encodeId=91cc9e0835cd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31545513340, createdName=ms1000001134092964, createdTime=Fri Jun 04 11:03:34 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952691, encodeId=16019526917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12d22296338, createdName=121f8ba0m90暂无昵称, createdTime=Wed Mar 31 15:56:16 CST 2021, time=2021-03-31, status=1, ipAttribution=)]
    2021-06-04 ms1000001134092964

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1081557, encodeId=29be108155e9b, content=棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a5561488012, createdName=luosujuan1984, createdTime=Sat Dec 18 16:13:28 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051057, encodeId=3735105105e53, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:13:25 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051056, encodeId=74cb1051056e4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c9c5389259, createdName=ms8000000063630784, createdTime=Tue Sep 14 11:11:59 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970835, encodeId=91cc9e0835cd, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=31545513340, createdName=ms1000001134092964, createdTime=Fri Jun 04 11:03:34 CST 2021, time=2021-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=952691, encodeId=16019526917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12d22296338, createdName=121f8ba0m90暂无昵称, createdTime=Wed Mar 31 15:56:16 CST 2021, time=2021-03-31, status=1, ipAttribution=)]
    2021-03-31 121f8ba0m90暂无昵称

    学习了

    0

相关指南

免疫检查点抑制剂相关心肌炎监测与管理中国专家共识（2020版）

中国抗癌协会(Chinese Anti-cancer Association) · 2020-11-20

免疫检查点抑制剂治疗恶性肿瘤的PET/CT评价专家共识（2020版）

中华医学会核医学分会(CSNM,Chinese Society of Nuclear Medicine) · 2020-09-30

2020 MASCC临床实践建议：免疫检查点抑制剂引起的严重皮肤毒性的管理

癌症支持疗法多国学会(MASCC,Multinational Association of Supportive Care in Cancer) · 2020-08-27

2020 MASCC临床实践建议：检查点抑制剂引起的免疫介导性心血管，风湿性和肾脏毒性的管理

癌症支持疗法多国学会(MASCC,Multinational Association of Supportive Care in Cancer) · 2020-08-27

免疫检查点抑制剂全程化药学服务指引（2019年版）

广东省药学会 · 2019-11-25

免疫检查点抑制剂相关消化系统不良反应的临床诊治建议

中国肿瘤科相关专家小组（统称） · 2019-10-30

拓展阅读

免疫检查点抑制剂相关血液毒性处理的临床诊疗建议

中国肿瘤科相关专家小组（统称） · 2019-10-30

免疫检查点抑制剂相关肾脏不良反应的临床诊治建议

国外肿瘤科相关专家小组（统称） · 2019-10-30

免疫检查点抑制剂相关皮肤不良反应诊治建议

中国肿瘤科相关专家小组（统称） · 2019-10-25

免疫检查点抑制剂相关神经系统不良反应的临床诊治建议

中国肿瘤科相关专家小组（统称） · 2019-10-30

免疫检查点抑制剂相关消化系统不良反应的临床诊治建议

中国肿瘤科相关专家小组（统称） · 2019-10-30

免疫检查点抑制剂全程化药学服务指引（2019年版）

广东省药学会 · 2019-11-25